Neovici AB (”Neovici” eller ”Bolaget”) är ett snabbväxande SaaS-bolag inom fintech som har utvecklat...
Redeye comments on Freemelt’s preliminary Q4 figures, which came in stronger than expected in terms ...
Redeye updates on EG7 ahead of Q4-results (due 7 February) where we expect continued sequential resu...
Redeye provides its comment on the news of the severe adverse event that occurred in the use of off-...
Mangold uppdaterar sin syn på greentech-bolaget ChargePanel efter det största avtalet i bolagets his...
Redeye provides a comment on today's news from Scandinavian Chemotech, where the company announced t...
Ahead of Relais' Q4 report, we take a slightly more cautious view on Q4 margins given the warm winte...
De underliggande portföljbolagen fortsätter att utvecklas väl och väntas växa omsättning respektive ...
Redeye comments on Truecaller ahead of its Q4 results, which are due on 18 February.
On January 22nd, STENOCARE announced the outcome of the conditional rights issue, which was subscrib...
Strong deliveries in Q4, sales +32% vs cons, EBIT +70% Guides for strong sales and order intake in 2...
Redeye comments on Thunderful Group ahead of its Q4 results, due on 13 February.
Q4e sales -4% y-o-y (-11% org.), adj. EBITA margin 4.
Q4e sales SEK 50m, flat y-o-y, EBIT SEK -0.6m (-2.1m) Somewhat more cautious on Perf.
Redeye comments on Invisio’s preannounced figures for Q4 which were much stronger than expected.
